Archives
-
Aptamer-Targeted mRNA for T-Cell Immunotherapy
2026-10-07
Paul and Al-Jamal describe an aptamer–mRNA platform designed to improve delivery to T cells, addressing the limited transfection efficiency of these immune cells. In murine ex vivo splenocytes, the targeted construct produced substantially greater reporter-associated expression than untargeted OX40 mRNA, while the chapter also highlights important limits around model scope, mechanism, and therapeutic translation.
-
PP 3 in ROS–Calcium Signaling Research
2026-10-06
Explore how 1-phenyl-1H-pyrazolo[3,4-d]pyrimidin-4-amine can strengthen interpretation of Src-related experiments without overstating what a negative control proves. This article connects PP 3 control logic with recent evidence on ROS, L-type calcium channels, and vascular contraction.
-
DOTMA and the Next Era of mRNA Translation
2026-10-06
A source-grounded perspective on how cationic lipid platforms may broaden mRNA vaccine translation, what the latest murine lymphoma evidence shows, and where DOTMA fits within a more flexible delivery landscape.
-
Pyridostigmine, α-Bungarotoxin, and Placental Necroptosis
2026-10-05
A 2026 Biochemical Pharmacology study links placental necroptosis with preeclampsia-like pathology in rats and identifies pyridostigmine-responsive α7 nicotinic acetylcholine receptor signaling as a potential regulatory pathway. Its combined human, animal, and cellular evidence supports a mechanistic hypothesis, while the pharmacological design and disease-model boundaries limit direct translation to clinical treatment.
-
Nicotinamide Riboside Chloride in RGC Research
2026-10-05
Nicotinamide Riboside Chloride (NIAGEN) is relevant to NAD+ biology, while iPSC-derived retinal ganglion cells offer a reproducible model for glaucoma and neurodegeneration research. The available evidence supports a conceptual connection, not a demonstrated therapeutic effect: the cited RGC study did not test NIAGEN, so its role remains a hypothesis for metabolic and cellular stress studies.
-
Spleen-Targeted mRNA LNPs for Anticancer Vaccines
2026-10-04
The 2025 reference study shows that lipid nanoparticle composition can strongly influence whether intravenously administered mRNA reaches splenic antigen-presenting cells. In a mouse anticancer-vaccination model, optimized CL15H6 LNPs produced approximately 75% tumor-growth suppression, but the findings remain preclinical and formulation-specific.
-
Lipo3K Transfection Reagent in Ferroptosis Research
2026-10-03
Explore how Lipo3K Transfection Reagent can support mechanistic studies of OTUD3, SLC7A11, ferroptosis, and sunitinib resistance in clear cell renal cell carcinoma. This article distinguishes product capabilities from published evidence and frames transfection as a tool for causal interpretation rather than a protocol.
-
FLAG tag Peptide (DYKDDDDK): Uses & Limits
2026-10-02
The FLAG tag Peptide, also called the DYKDDDDK peptide, is an eight-residue reagent for antibody-based recombinant protein purification and analysis. Its enterokinase-compatible sequence supports gentle elution from anti-FLAG M1 and M2 affinity resins, while 3X FLAG constructs require a different peptide.
-
Two-Component Liposomes for mRNA Cancer Vaccines
2026-10-01
Pedersen and colleagues describe a stable two-component cationic liposome system that complexes with mRNA by simple admixing rather than requiring a fully manufactured four-lipid nanoparticle. In a murine lymphoma model, optimized CAF04:mRNA formulations generated functional CD8+ T-cell responses and delayed tumor growth, supporting further study of simplified, potentially freeze-dried cancer vaccine platforms.
-
DMG-PEG2000-N3: From Clickable Lipid to LNP Strategy
2026-10-01
A translational framework for using DMG-PEG2000-N3 as a modular PEG-lipid building block, connecting click-enabled bioconjugation with liposome development, RNA-LNP characterization, drying strategy, and clinical-readiness decisions.
-
Parthenolide, ROS, and Lymphoid Cancer Apoptosis
2026-09-30
Jorge and colleagues show that parthenolide suppresses metabolic activity and promotes oxidative-stress-associated apoptosis across diverse B- and T-lineage lymphoid malignancy models. By combining resazurin-based viability measurement with flow cytometry and gene-expression analysis, the study links NF-κB-relevant biology to mitochondrial dysfunction, ROS accumulation, and glutathione depletion while emphasizing cell-line-specific responses.
-
DMG-PEG2000-NH2: LNP Workflow Guide
2026-09-30
DMG-PEG2000-NH2 combines a PEG2000 spacer with a reactive primary amine for controllable biomolecule conjugation and lipid-particle surface engineering. This guide translates that chemistry into practical liposome, lipid nanoparticle, and siRNA workflow decisions while separating product applications from findings in the reference antimycobacterial study.
-
Sulfaphenazole Optimization Against M. tuberculosis
2026-09-29
Chen and colleagues used systematic sulfaphenazole optimization to retain antimycobacterial activity while reducing CYP2C9 inhibition, a liability associated with potential drug–drug interactions. Compound 10d emerged as the most balanced lead in the reported series, although the findings remain an in vitro discovery result rather than evidence of clinical efficacy.
-
SVA 3A/2B, DDX23, and Caspase-Mediated Escape
2026-09-29
A 2025 Journal of Virology study identifies a two-sided interaction between the SVA nonstructural proteins 3A and 2B and the host RNA helicase DDX23. Its combination of genetic perturbation, caspase-pathway analysis, and reverse genetics shows how DDX23 restricts SVA while viral proteins counteract this defense through distinct caspase-dependent mechanisms.
-
DMG-PEG2000-NH2: From Linker to Translation
2026-09-28
A mechanistic and translational perspective on DMG-PEG2000-NH2, connecting amide chemistry, PEG-enabled formulation, siRNA encapsulation, and evidence-led development without overstating what current data demonstrate.